Becton Dickinson Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 5/6
Becton Dickinson kazançlarla iyi bir şekilde karşılanan, mevcut getirisi 2.81% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi, temettüden önceki tarihi 30th June, 2026 olan 9th June, 2026 dir.
Anahtar bilgiler
2.8%
Temettü verimi
1.2%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 4.0% |
| Gelecekteki Temettü Verimi | 2.6% |
| Temettü Büyümesi | 4.7% |
| Bir sonraki temettü ödeme tarihi | 30 Jun 26 |
| Eski temettü tarihi | 09 Jun 26 |
| Hisse başına temettü | n/a |
| Ödeme oranı | 68% |
Son temettü ve geri alım güncellemeleri
Recent updates
BDX: Cautious Reset In FY26 Expectations And Execution Risks Will Shape Outlook
Becton Dickinson's analyst price target has been reset from $183 to $157 as analysts factor in more cautious revenue growth, slightly softer profit margins, a higher discount rate, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research around Becton Dickinson reflects a more cautious tone, with a series of price target resets and neutral stances shaping expectations for risk and reward.Becton, Dickinson: Value Or Overvalued Even Now?
Apr 20
BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential
Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside
Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside
Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential
The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns
Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.
BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup
Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05
Jan 31
BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook
Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential
Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook
We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds
Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05
Nov 24BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds
Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings
Nov 16Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05
Nov 09BDX Will Unlock New Growth Following Planned 2026 Business Separation
Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.Becton, Dickinson and Company: It's Wait And See For Me
Apr 27Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline
Mar 30Yaklaşan Temettü Ödemesi
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: BDX şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.
Büyüyen Temettü: BDX şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.
Piyasaya Karşı Temettü Getirisi
| Becton Dickinson Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (BDX) | 2.8% |
| Pazarın Alt %25'i (US) | 1.4% |
| Pazarın En İyi %25'i (US) | 4.2% |
| Sektör Ortalaması (Medical Equipment) | 2.2% |
| Analist tahmini (BDX) (3 yıla kadar) | 2.6% |
Önemli Temettü: BDX 'in temettüsü ( 2.81% ), US piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.4% ) daha yüksektir.
Yüksek Temettü: BDX 'in temettüsü ( 2.81% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.22% ) kıyasla düşüktür.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Makul ödeme oranı ( 68% ) ile BDX 'un temettü ödemeleri kazançlarla karşılanmaktadır.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Oldukça düşük nakit ödeme oranı ( 45.5% ) ile BDX 'un temettü ödemeleri nakit akışları tarafından iyi bir şekilde karşılanmaktadır.
Güçlü temettü ödeyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/01 08:05 |
| Gün Sonu Hisse Fiyatı | 2026/05/01 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/09/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Becton, Dickinson and Company 35 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |